Novo Nordisk's Victoza gets NICE nod for diabetes
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has given a partial green light to funding Novo Nordisk's Victoza (liraglutide) for NHS patients with diabetes type 2.